Pegylated interferon alpha2a for Agnogenic Myeloid Metaplasia

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT
Agnogenic Myeloid Metaplasia+1 More
Pegylated interferon alpha2a - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This is a single site, open-label, dose de-escalation, Phase 1 study of pegylated interferon alfa-2a administered after alloHCT in subjects with primary or secondary myelofibrosis. Part 1 of the study will assess the rate of dose-limiting toxicities (DLTs) during the DLT evaluation period and identify the Recommended Phase 2 Dose (RP2D). Once the RP2D is identified, 6 additional patients will be enrolled in the expansion cohort.

Eligible Conditions

  • Agnogenic Myeloid Metaplasia

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Agnogenic Myeloid Metaplasia

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: 3 years

3 years
Assess leukemia-free survival (LFS) in the study population.
Assess the incidence of acute graft versus host disease (GVHD) in the study population
Assess the rate of treatment-related mortality in the study population.
Assess the safety of pegylated interferon alfa-2a in the study population.
Assess the tolerability of pegylated interferon alfa-2a in the study population.
Day 86
Rate of dose-limiting toxicities (DLTs) during the DLT evaluation period

Trial Safety

Safety Progress

1 of 3

Other trials for Agnogenic Myeloid Metaplasia

Trial Design

1 Treatment Group

Treatment: All Patients
1 of 1
Experimental Treatment

18 Total Participants · 1 Treatment Group

Primary Treatment: Pegylated interferon alpha2a · No Placebo Group · Phase 1

Treatment: All Patients
Drug
Experimental Group · 1 Intervention: Pegylated interferon alpha2a · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pegylated interferon alpha2a
2020
Completed Phase 2
~20

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 3 years
Closest Location: Huntsman Cancer Institute at the University of Utah · Salt Lake City, UT
Photo of Salt Lake City  1Photo of Salt Lake City  2Photo of Salt Lake City  3
2008First Recorded Clinical Trial
1 TrialsResearching Agnogenic Myeloid Metaplasia
12 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are a male or female aged ≥ 18 years.
You are eligible to undergo a myeloablative or reduced intensity conditioning regimen.
You have a 10/10 HLA matched related or matched unrelated donor.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.